Alzheimer’s disease (AD) causes unrelenting, progressive cognitive impairments, but its
course is heterogeneous, with a broad range of rates of cognitive decline 1 . The spread of tau …

Colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34) are functional ligands of the
CSF1 receptor (CSF1R) and thus are key regulators of the monocyte/macrophage lineage. We …

The pathogenesis and clinical heterogeneity of Parkinson’s disease (PD) have been
evaluated from molecular, pathophysiological, and clinical perspectives. High-throughput …

Aggregates of hyperphosphorylated tau protein are a pathological hallmark of more than 20
distinct neurodegenerative diseases, including Alzheimer’s disease, progressive …

Reversible janus associated kinase (JAK) inhibitors such as tofacitinib and decernotinib
block cytokine signaling and are efficacious in treating autoimmune diseases. However, …

Krabbe Disease (KD) is an autosomal metabolic disorder that affects both the central and
peripheral nervous systems. It is caused by a functional deficiency of the lysosomal enzyme, …

In the version of this article initially published, the units used for TEER results (ohm cm–2)
were incorrect in the third, fourth, fifth and final sentences of the fourth paragraph in the first …

The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, non-receptor
tyrosine kinases whose activities have been associated in the literature and the clinic with …

The pathogenesis and clinical heterogeneity of Parkinson’s disease have been evaluated
from molecular, pathophysiological, and clinical perspectives. High-throughput proteomic …

The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for
clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a …